Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment

L. Golubev, M. Gorbunova, S. Babak, A. Tatarskiy (Moscow, Russia)

Source: Annual Congress 2004 - Clinical aspects of OSA
Session: Clinical aspects of OSA
Session type: Thematic Poster Session
Number: 785
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
L. Golubev, M. Gorbunova, S. Babak, A. Tatarskiy (Moscow, Russia). Sleep architecture in COPD patients during salmeterol versus ipratropium bromide treatment. Eur Respir J 2004; 24: Suppl. 48, 785

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Sleep architecture in COPD patients during salmeterol versus tiotropium bromide treatment
Source: Eur Respir J 2006; 28: Suppl. 50, 199s
Year: 2006

Influence of higher than conventional doses of salbutamol or ipratropium bromide on bronchodilation induced by a regular treatment with tiotropium in patients suffering from stable COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 356s
Year: 2007

Improvement in dyspnea with fluticasone/salmeterol compared with salmeterol or ipratropium in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 88s
Year: 2004

Comparative study of two years treatment with salmeterol alone and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2004; 24: Suppl. 48, 342s
Year: 2004

Lung function response to budesonide and ipratropium bromide in COPD patients who continue smoking
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

A comparison of early bronchodilating responses of Salbutamol, Ipratropium bromide, and the combination of Ipratropium bromide-Salbutamol in stable patients with COPD or asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 246s
Year: 2002

Comparative study of one-year treatment with salmeterol along, and in combination with ipratropium bromide and beclometazone dipropionate in patients with chronic obstructi e pulmonary diseases (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 286s
Year: 2003

Acute effect of formoterol, salmeterol, albuterol, oxitropium bromide and placebo on FEV1, inspiratory capacity and dyspnoea in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 380s
Year: 2001

Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children
Source: Eur Respir J 2004; 24: Suppl. 48, 167s
Year: 2004

Salmeterol or ipratropium bromide/fenoterol in stable mild-to-moderate COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 426s
Year: 2001

Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
Source: Annual Congress 2013 –New bronchodilators for COPD management
Year: 2013

Reversibility effects of ipratropium bromide and terbutalin sulphate in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 72s
Year: 2001

Pulmonary function and bronchodilator response to albuterol, ipratropium bromide and association of albuterol and ipratropium bromide in children with cystic fibrosis (CF)
Source: Eur Respir J 2003; 22: Suppl. 45, 229s
Year: 2003

Evaluation of airway sGaw in Japanese COPD patients treated with triple therapy using salmeterol/fluticasone propionate 50/250 and tiotropium bromide
Source: International Congress 2015 – COPD: interesting notes
Year: 2015


Formoterol or tiotropium bromide do not influence isolated nocturnal hypoxemia in stable COPD
Source: Eur Respir J 2005; 26: Suppl. 49, 294s
Year: 2005

Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD I
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Efficacy and safety of twice-daily aclidinium bromide compared with tiotropium and placebo in patients with moderate to severe COPD
Source: Annual Congress 2010 - Regulation of airway hyperresponsiveness and bronchodilators
Year: 2010


Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study
Source: Eur Respir J 2012; 40: 1106-1114
Year: 2012



Is there any point in treatment of patients with chronic obstructive pulmonary diseases with salmeterol and ipratropium bromide, alone and in combination?
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002

Cardiopulmonary effects of inhaled ipratropium bromide and its combination with fenoterol in patients with bronchial asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 58s
Year: 2002